Broad Spectrum Antibiotics
Broad Spectrum Antibiotics - Related Videos
11:34
High-throughput Screening for Broad-spectrum Chemical Inhibitors of RNA Viruses
0 Views •
Cited by 14 •
2014
In vitro assays to measure virus replication have been greatly improved by the development of recombinant RNA viruses expressing luciferase or other enzymes capable of bioluminescence. Here we detail a high-throughput screening pipeline that combines such recombinant strains of measles and chikungunya viruses to isolate broad-spectrum antivirals from chemical libraries.
02:37
The Electromagnetic Spectrum
0 Views •
2020
The electromagnetic spectrum consists of all the types of electromagnetic radiation arranged according to their frequency and wavelength. Each of the various colors of visible light has specific frequencies and wavelengths associated with them, and you can see that visible light makes up only a small portion of the electromagnetic spectrum. Because the technologies developed to work in various parts of the electromagnetic spectrum are different, for reasons of convenience and historical...
13:39
Antibiotic Susceptibility Testing: Epsilometer Tests to Determine MIC Values of Two Antibiotics and Evaluate Antibiotic Synergy
0 Views •
2023
Source: Anna Bläckberg1, Rolf Lood1 1 Department of Clinical Sciences Lund, Division of Infection Medicine, Biomedical Center, Lund University, 221 00 Lund Sweden Knowledge of the interactions between antibiotics and bacteria is important in understanding how microbes evolve antibiotic resistance. In 1928, Alexander Fleming discovered penicillin, an antibiotic that exerts its antibacterial function by interfering with cell wall regeneration (1). Other antibiotics with diverse mechanisms of...
01:19
IR Spectrum
0 Views •
2024
When infrared (IR) radiation passes through a molecule, the bonds stretch or bend by absorbing the radiation. This absorption creates the molecule's absorption spectrum, which is the plot of its percentage transmittance versus wavenumber. Transmittance is defined as the ratio of the radiant power passing through a sample to that from the radiation's source. Multiplying the transmittance by 100 gives the percent transmittance (%T), which varies between 100% (no absorption) and 0% (complete...
10:02
Executive Function in Autism Spectrum Disorder
0 Views •
2023
Source: Laboratories of Jonas T. Kaplan and Sarah I. Gimbel—University of Southern California Attention, working-memory, planning, impulse control, inhibition, and mental flexibility are important components of human cognition that are often referred to as executive functions. Autism spectrum disorder is a developmental disorder that is characterized by impairments in social interaction, communication, and repetitive behaviors. It is a disorder that lasts a lifetime, and is thought to affect...
FAQs
Broad-spectrum antibiotics do not share one universal molecular target. Depending on the drug, antibacterial activity may result from interference with cell-wall synthesis, protein production, DNA replication, or metabolic pathways. This distinction matters because the affected process and the organism’s susceptibility help determine whether treatment will work, even when several bacterial species are potentially involved.
The main biological cost of broad activity is collateral disruption of normal microbiota. Removing susceptible members of these microbial communities changes the surrounding biological balance, while exposure also creates selection pressure favoring bacteria that can survive the drug. These effects explain why broad coverage should not automatically be equated with better treatment or used without reassessment.
A wide activity range does not guarantee effectiveness against every bacterium. The drug may act on a relevant essential process, yet the particular organism can still be susceptible or not. Therefore, identifying the causative organism and using culture-based susceptibility testing are important for distinguishing likely coverage from demonstrated effectiveness.
Initial broad coverage is most relevant when a serious infection requires prompt treatment but the causative pathogen has not yet been identified, or when more than one bacterium may be involved. In these settings, clinicians balance the need to address plausible organisms quickly against microbiota disruption and resistance selection, then use diagnostic information to support stewardship.
Diagnosis establishes the clinical context, while culture-based testing helps determine which organism is present and whether it is susceptible to a selected drug. Together, these steps provide evidence for moving beyond an initial broad choice when appropriate. They also reduce reliance on coverage assumptions and support more deliberate antibiotic stewardship.
Stewardship provides a decision framework that balances rapid treatment with the consequences of unnecessary broad activity. In biology and medicine, it links drug selection to diagnostic evidence, likely bacterial susceptibility, and possible effects on normal microbiota and resistance. Its purpose is not simply to avoid these drugs, but to limit avoidable ecological and evolutionary costs.